1Park SH,Shin WY, Lee EY, et al. The impact of hyperurice-mia on in-hospital mortality and incidence of acute kidney inju-ry in patients undergoing percutaneous coronary intervention[Jl. Circulation Journal, 2011,75(3): 692-697.
2Kansui Y,Ohtsubo T,Goto K, et al. Association of serum u-ric acid with blood pressure in Japanese men: Cross-sectionalstudy in work-site group [J]. Circulation Journal f 2011, 75(12): 2827-2832.
3Fagugli RM, Gentile G,Ferrara G, et al. Acute renal and he-patic failure associated with allopurinol treatment [ J]. ClinNephrol, 2008,70(6): 523*526.
4Halevy S,Ghislain PD, Mockenhaupt M,et al. Allopurinol isthe most common cause of Stevens-Johnson syndrome and tox-ic epidermal necrolysis in Europe and Israel[J]. Journal of theAmerican Academy of Dermatology? 2008,58(1): 25-32.
5Becker MA, Schumacher HR, Wortmann RL, et al. Febux-ostat compared with allopurinol in patients with hyperuricemiaand gout[J]. N Engl,2005, 353(353): 2450-2461.
6Akira Sezai, Masayoshi Soma, Kin-ichi Nakata, et al. Com-parison of Febuxostat and Allopurinol for Hyperuricemia in(8): 2043-2049.
7Matsumoto K, Okamoto K. Ashizawa N, et al. FYX-051 : Anovel and potent hybrid-type inhibitor of xanthine oxidoreduc-tase[J]. Journal of Pharmacology Experimental Therapeu-tics, 2010, 336(1): 95-103.
8Burns CM, Wortmann RL. Gout therapeutics: New drugs foran old disease[J]. Lancet, 2011, 377(9760) : 165-t77.
9Tatuo H, Iwao O. A repeated oral administration study of fe-buxostat (TMX-67), a non-purine-selective inhibitor of xan-thine oxidase in patients with impaired renal function in Japan:pharmacokinetic and pharmacodynamic study [J]. Journal ofClinical Rheumatology Practical Reports on Rheumatic &-Musculoskeletal Diseases,2011,17(4 Suppl 2) : 27-34.
